Younossi ZM, Yilmaz Y, Yu ML, et al. - Findings demonstrate a high comorbidity burden as well as impaired quality of life among nonalcoholic fatty liver disease (NAFLD) patients seen in real-world practices in different countries.

• Data were obtained from NAFLD patients seen in real-world practices and enrolled in the Global NAFLD/NASH (nonalcoholic steatohepatitis) Registry, to evaluate the clinical presentation and patient-reported outcomes (PROs) among NAFLD patients from different countries.

• NAFLD patients (n = 5,691), across the global burden of disease super-regions, were noted to be the oldest in Latin America and Eastern Europe and youngest in South Asia.

• Variations in cirrhosis rates were evident (12%–21%), the North Africa/Middle East and Eastern Europe showed the highest rates.

• Compared with general population norms, NAFLD patients exhibited lower Chronic Liver Disease Questionnaire–NASH and Functional Assessment of Chronic Illness Therapy–Fatigue PRO scores, and Eastern Europe and North Africa/Middle East showed the lowest PRO scores.

• Younger age, female gender, and nonhepatic comorbidities including fatigue were independent predictors of lower PRO scores, and a substantial PRO improvement was seen in patients whose fatigue scores improved over time.

• Of the Global NAFLD/NASH Registry patients, nearly 8% exhibited: a lean body mass index, with fewer metabolic syndrome components, fewer comorbidities, less cirrhosis, and significantly better PRO scores.